Kymera Therapeutics

Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology

Series B financing led by 6 Dimensions Capital, Bessemer Venture Partners, and Pfizer Ventures Financing to enable the advancement of lead program into clinical development and support the progression of additional programs Cambridge, Mass. (Nov. 13, 2018) – Kymera Therapeutics Inc., a